Alnylam, Isis Strike Deal for Single-Stranded RNAi Technology

Under the deal, Isis has co-exclusively licensed to Alnylam the rights to use its ssRNAi technology in drug development. Isis could potentially receive $31 million in licensing fees under the agreement.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.